Lighten the Load: Updates in Obesity Management
This CE activity will familiarize attendees with the identification and management of patients with obesity by summarizing recommendations from relevant primary literature, 2022 AGA guideline, 2013 ACC/AHA/TOS guideline, 2016 AACE/ACE guideline on managing obesity, and the 2023 Obesity Treatment Guidelines.
Target Audience
- Pharmacists
- Pharmacy Technicians
- Other Healthcare Professionals
Learning Objectives
Pharmacists learning objectives
At the conclusion of this activity, pharmacists should be able to:
- Define screening and diagnosis for obesity.
- Analyze the role of weight loss medications and bariatric surgery in obesity management.
- Compare drug classes approved for the treatment of obesity.
- Identify ideal treatment options for patients with obesity and other comorbidities.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Identify common medications used in the treatment of obesity.
- Recognize cost barriers associated with obesity treatment options.
Additional Information
Attachment | Size |
---|---|
Helpful Tips for Users - Vizient CE System.pdf | 134.66 KB |
Planning committee
Rachel Rendon, PharmD, BCPS
Clinical Pharmacist
ChristianaCare
Amanda Schartel, PharmD, BCACP
Clinical Pharmacist Specialist, Primary Care
ChristianaCare
Faculty
Kirollos Daoud, PharmD
PGY-2 Ambulatory Care Pharmacist Resident
ChristianaCare
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of Content Validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.”
Evidence-based Content: “Low/absence of evidence-based topics are mentioned within this activity.”
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Designation Statement(s)
PHARMACY
Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.
UAN JA0006103-9999-23-354-L01-P
UAN JA0006103-9999-23-354-L01-T
OTHER
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance